v3.26.1

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 71,793	$ 13,886
Restricted cash and cash equivalents	100	100
Prepaid expenses and other current assets	3,318	2,341
Total current assets	75,211	16,327
Operating lease right-of-use assets	963	925
Goodwill	1,914	1,914
Deposits and other assets	257	266
Total assets	78,345	19,432
Current liabilities:
Accounts payable	2,948	3,500
Accrued expenses and other current liabilities	3,525	5,466
Operating lease liabilities	544	544
Total current liabilities	7,017	9,510
Operating lease liabilities, non-current	457	457
Total liabilities	7,474	9,967
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, $0.0001 par value; 350,000,000 shares authorized, 153,103,459 and 73,977,459 shares issued and outstanding at December 31, 2025 and 2024, respectively	15	7
Additional paid-in capital	345,844	257,583
Accumulated deficit	(274,988)	(248,125)
Total stockholders’ equity	70,871	9,465
Total liabilities and stockholders’ equity	$ 78,345	$ 19,432

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

SELLAS Life Sciences Group, Inc. 10-K